Time optimization of gadobutrol-enhanced brain MRI for metastases and primary tumors using a dynamic contrast-enhanced imaging.

Abstract

BACKGROUND:

Recent advances in rapid imaging techniques necessitate the reconsideration of the optimal imaging delay time for contrast-enhanced T1-weighted imaging. The aim of our study was to determine the optimal contrast-enhanced T1-weighted imaging delay time from the obtained time-signal intensity curve (TIC) using gadobutrol in patients with brain metastases, primary brain tumors, and meningiomas.

METHODS:

This prospective study enrolled 78 patients with brain metastases (n = 39), primary brain tumors (n = 22), or meningiomas (n = 17) who underwent 7-min dynamic contrast-enhanced imaging with single-dose gadobutrol. Based on the time-to-peak (TTP) derived from the TIC, we selected four different time points for analysis. Lesion conspicuity, enhanced rate (ER) and contrast rate (CR) of 116 index lesions were evaluated. Statistical comparisons were made for the four different time points using the Friedman test.

RESULTS:

Maximum TTP (305.20 ± 63.47 s) was similar across all three groups (p = 0.342). Lesion conspicuity, CR and ER increased over time in all index lesions; however, no significant difference between the 5- and 7-min images was observed. The longest diameter in all groups differed significantly among time points (p < 0.001); the perpendicular diameter did not differ between the 5- and 7-min images.

CONCLUSIONS:

Maximum contrast enhancement and lesion conspicuity was achieved 5-7 min after a single gadobutrol injection for brain metastases detection and for primary brain tumor/meningioma evaluation. Acquiring images 5 min after gadobutrol injection is the optimal timing for brain tumor detection during MRI work-up.

• Authors: Jeemin Seo, Changmok Lim, Kye Young Lee, Young-Cho Koh, Won-Jin Moon
• Journal: BMC medical imaging (BMC Med Imaging) Vol. 22 Issue 1 Pg. 180 (10 17 2022) ISSN: 1471-2342 [Electronic] England
• PMID: 36253718 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Contrast Media
• Organometallic Compounds
• gadobutrol

Topics

• Brain
• Brain Neoplasms (diagnostic imaging, secondary)
• Contrast Media
• Humans
• Magnetic Resonance Imaging (methods)
• Meningeal Neoplasms
• Meningioma
• Organometallic Compounds
• Prospective Studies